https://origin.rootz.global/api/company/REGN| Name | Type | Description |
|---|---|---|
| EYLEA HD (aflibercept 8 mg) | service | Injectable treatment for wAMD, DME, DR, and RVO approved in the U.S., EU, and Japan. |
| EYLEA (aflibercept) | service | Injectable treatment for wAMD, DME, DR, RVO, mCNV, NVG, and ROP approved in multiple territories. |
| Dupixent (dupilumab) | service | Injectable treatment for atopic dermatitis, asthma, CRSwNP, COPD, EoE, prurigo nodularis, CSU, and bullous pemphigoid. |
| Libtayo (cemiplimab) | service | Injectable treatment for NSCLC, BCC, CSCC, and cervical cancer in the U.S. and EU. |
| Praluent (alirocumab) | service | Injectable treatment for cardiovascular risk reduction and hypercholesterolemia in the U.S. and EU. |
| Kevzara (sarilumab) | service | Injectable treatment for rheumatoid arthritis, polymyalgia rheumatica, and pJIA in the U.S., EU, and Japan. |
| Evkeeza (evinacumab) | service | Injectable treatment for homozygous familial hypercholesterolemia in the U.S., EU, and Japan. |
| Ordspono (odronextamab) | service | Treatment for follicular lymphoma and diffuse large B-cell lymphoma approved in the U.S. |
| Lynozyfic (linvoseltamab) | service | Treatment for relapsed/refractory multiple myeloma approved in the U.S. and EU. |
| Inmazeb (atoltivimab, maftivimab, odesivimab) | service | Injectable treatment for Zaire ebolavirus infection approved in the U.S. |
| Partner | Type | Description |
|---|---|---|
| Bayer | development | Collaboration for EYLEA and EYLEA HD outside the United States. |
| Sanofi | development | Collaboration for Dupixent, Kevzara, and ZALTRAP; Sanofi commercializes Praluent outside the U.S. |
| Ultragenyx | licensing | Ultragenyx is responsible for development and commercialization of Evkeeza outside the United States. |
| Kiniksa | licensing | Kiniksa is responsible for development and commercialization of ARCALYST. |
View all SEC EDGAR filings: EDGAR Company Page
Structured filing index: /api/company/REGN/filings